EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokoll

Evaluating Dexamethasone as an Adjuvant in the Antagonist Protocol in PCOS Patients Undergoing IVF/ICSI: A Randomized Controlled Trial

Fahimeh Alizadeh, Malihe Amirian, Nayereh Khadem, Malihe Afiat, Malihe Mahmoudinia, Sahar Ardalan Khales, Fatemeh Barani Moghaddam, Farzaneh Afshar Delkhah, Hassan Mehrad-Majd

Reproductive Sciences · 2025

DOI: 10.1007/s43032-025-01895-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Reproductive Sciences, 2025. Verfasst von Fahimeh Alizadeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Family and the Youth of Population Support Research Center, Department of Obstetrics and Gynecology, School of Medicine, Imam Reza Hospital, Mashhad …. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Dexamethasone, Fertilization in Vitro, Sperm Injections, Intracytoplasmic. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Mashhad University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, often requiring assisted reproductive technologies such as in vitro fertilization (IVF). Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication in PCOS patients undergoing IVF. Dexamethasone, a synthetic glucocorticoid, may improve IVF outcomes by reducing inflammation and optimizing ovarian stimulation. Polycystic ovarian syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, often requiring assisted reproductive technologies such as in vitro fertilization (IVF). Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complications in PCOS patients undergoing IVF. This study evaluated the effect of dexamethasone in the gonadotropin-releasing hormone (GnRH) antagonist protocol for patients with PCOS undergoing IVF/ICSI. METHODS: In this randomized, single-blind trial, 189 infertile PCOS patients were randomly assigned to either the dexamethasone group or the control group. The dexamethasone group received 0.5 mg orally twice daily, along with gonadotropins. The control group received gonadotropin alone. Primary outcomes included mature oocytes (metaphase II), follicle to oocyte index (FOI), clinical pregnancy and live birth rates. Secondary outcomes included gonadotropin dose, oocytes retrieved, embryo quality, and OHSS incidence. RESULTS: Compared to the control group, the dexamethasone group showed significant improvements, including a higher number of mature oocytes (15.47 vs. 13.84, p < 0.001) and FOI (75.10 vs. 69.65, p = 0.045). Additionally, the dexamethasone group had a higher clinical pregnancy rate (43.8% vs. 22.6%, p = 0.002) and live birth rate (34.4% vs. 9.7%, p < 0.001), as well as an increased number of top-quality embryos (6.63 vs. 6.45, p < 0.001). No significant differences were observed in gonadotropin dose and OHSS incidence. CONCLUSIONS: Dexamethasone significantly improved IVF outcomes in PCOS patients, including oocyte quality and pregnancy rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeDexamethasoneFertilization in VitroSperm Injections, IntracytoplasmicGonadotropin-Releasing HormoneOvulation InductionInfertility, FemaleHumansFemalePregnancyAdultPregnancy RateSingle-Blind MethodTreatment OutcomeOvarian Hyperstimulation Syndrome

Stichwörter der Autor:innen

Antagonist protocolDexamethasoneIVFPolycystic ovarian syndrome

Substanzen

DexamethasoneGonadotropin-Releasing Hormone

Autor:innen und Institutionen

  • Family and the Youth of Population Support Research Center, Department of Obstetrics and Gynecology, School of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Family and the Youth of Population Support Research Center, Department of Obstetrics and Gynecology, School of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. afiatm@mums.ac.ir.
  • Clinical Research Development Unit, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

Förderung

  • Mashhad University of Medical Sciences

Zitieren

APA

Alizadeh, F., Amirian, M., Khadem, N., Afiat, M., Mahmoudinia, M., Khales, S. A., Moghaddam, F. B., Delkhah, F. A., & Mehrad-Majd, H. (2025). Evaluating Dexamethasone as an Adjuvant in the Antagonist Protocol in PCOS Patients Undergoing IVF/ICSI: A Randomized Controlled Trial. Reproductive Sciences. https://doi.org/10.1007/s43032-025-01895-7

Vancouver

Alizadeh F, Amirian M, Khadem N, Afiat M, Mahmoudinia M, Khales SA, et al. Evaluating Dexamethasone as an Adjuvant in the Antagonist Protocol in PCOS Patients Undergoing IVF/ICSI: A Randomized Controlled Trial. Reproductive Sciences. 2025. doi:10.1007/s43032-025-01895-7

BibTeX
@article{Alizadeh2025,
  author = {Alizadeh, Fahimeh and Amirian, Malihe and Khadem, Nayereh and Afiat, Malihe and Mahmoudinia, Malihe and Khales, Sahar Ardalan and Moghaddam, Fatemeh Barani and Delkhah, Farzaneh Afshar and Mehrad-Majd, Hassan},
  title = {Evaluating Dexamethasone as an Adjuvant in the Antagonist Protocol in PCOS Patients Undergoing IVF/ICSI: A Randomized Controlled Trial},
  journal = {Reproductive Sciences},
  year = {2025},
  doi = {10.1007/s43032-025-01895-7}
}
Kostenlos starten →